健择联合顺铂治疗晚期非小细胞肺癌的疗效  

Combination of Gemitabine and Cisplatin for Treating Advanced Non-small Cell Lung Cancer.

作　　者：郑少青[1] 

机构地区：[1]海南省农垦总局医院肿瘤内科,570311

出　　处：《中华临床医学杂志》2007年第3期24-24,23,共2页Chinese Journal of Clinical Practical Medicine

摘　　要：目的 目前临床上绝大多数非小细胞肺癌（non-small cell lung cancer,NSCLC）患者缺乏有效的治疗方法和药物。本文用健择联合顺铂两药联合化疗，目的 在于探讨该方案的临床疗效及不良反应。方法20例患者均为晚期NSCLC，化疗方案为健择1000mg／m^2静滴≥3h，第1、8、15天、顺铂80mg／m^2静滴≥2h，第2天，28d为1周期，连用2周期为1疗程。结果 20例患者中，PR5例，有效率为25％，所有病例中除2例出现转移外其余均可见病灶好转或稳定。中位缓解期6个月，中位生存期9个月。主要不良反应按WHO标准11。发生率分别为血液学20％（4／20）。脱发65％（13／20），恶心、呕吐5％（10／20），骨髓抑制5％（1／20），经用集落细胞刺激因子。输血小板及止吐处理和停止化疗后可自行缓解。结论 健择联合顺铂治疗晚期NSCLC有一定的疗效，其毒性反应病人可以耐受。为晚期非小细胞肺癌提供了一种切实可行的治疗方案。Objective At present, great majority of patients suffering from non-small cell lung cancer（NSCLC） lacks effective treatments and medicines. This study was intended to use gemitabine and cisplatin for treating NSCLC patients,and to observe curative efficacy and the ill-effects, Methods All the 20 cases were NSCLC in the late stage. The chemotherapy plan： Gemitabine（1000mg/m^2） was given intravenously on day 1,8 and 15,and cisplatin（80mg/m^2）was given intraveonusly on day 2. The treatment took 28 days,and the treatment perild needed two such treatments. Results 5 out of the 20 cases were PR, so the curative efficacy was 25%. Metastasis occurred in 2 of them. The remaining were at resolving and stationary stage. The median paracme and survival times were 6 and 9 months respectively. According to the WHO standard Ⅲ, the adverse reactions included hematological changes（20%）, alopecia（65%）, disgusting and vomiting（50%）, and the marrow repress（5%）.Platelet transfusion with CSF and antiemetic alleviated the side effects.Patients alleviatde by themselves after the drugs had been stopped. Conclusion Combined chemotherapy of gemitabine and cisplatin had some curative efficacy for the NSCLC. The patients could bear the side effects.

关 键 词：晚期非小细胞肺癌 药物治疗 健择 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]